|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Clinical use of bone-targeting radiopharmaceuticals with focus on alpha-emitters显示文摘Various single or multi-modality therapeutic options are available to treat pain of bone metastasis in patients with prostate cancer.Different radionuclides that emitβ-rays such as 153Samarium and 89Strontium and achieve palliation are commercially available.In contrast toβ-emitters,223Radium as a a-emitter has a short path-length.The advantage of the a-emitter is thus a highly localized biological effect that is caused by radiation induced DNA double-strand breaks and subsequent cell killing and/or limited effectiveness of cellular repair mechanisms.Due to the limited range of the a-particles the bone surface to red bone marrow dose ratio is also lower for 223Radium which is expressed in a lower myelotoxicity.The a emitter 223Radium dichloride is the first radiopharmaceutical that significantly prolongslife in castrate resistant prostate cancer patients with wide-spread bone metastatic disease.In a phaseⅢ,randomized,double-blind,placebo-controlled study 921patients with castration-resistant prostate cancer and bone metastases were randomly assigned.The analysis confirmed the 223Radium survival benefit compared to the placebo(median,14.9 mo vs 11.3 mo;P<0.001).In addition,the treatment results in pain palliation and thus,improved quality of life and a delay of skeletal related events.At the same time the toxicity profile of223Radium was favourable.Since May 2013,223Radium dichloride(Xofigo?)is approved by the US Food and Drug Administration. | Hinrich A Wieder Michael Lassmann Martin S Allen-Auerbach Johannes Czernin Ken Herrmann | 2014 | World Journal of Radiology2014，6，7： | 4 |
| 2 | Demyelination ver-sus remyelination in progressive multiple sclerosis 显示文摘 | Bramow S Frischer JM Lassmann H | 2010 | Brain2010，133，： | 1 |
| 3 | Predictive value of Aurora-A/STK15 expression for late stage epithelial ovarian cancer patients treated by adjuvant chemotherapy显示文摘 | Lassmann S Shen Y Jütting U | 2007 | Clin Cancer Res2007，13，14： | 1 |
| 4 | STAT3 mRNA and pro- tein expression in colorectal cancer: effects on STAT3-inducible targets linked to cell survival and proliferation 显示文摘 | Lassmann S Schuster I Walch A | 2007 | J Clin Pathol2007，60，2： | 1 |
| 5 | STAT3 mRNA and protein expression in colorectal cancer:effects on STAT3 in ducible targets linked to cell survival and proliferation显示文摘 | Lassmann S Schuster I Walch A | 2007 | J Clin Pathol2007，60，2： | 1 |
| 6 | STAT3 mRNAand protein expression in colorectal cancer: effects onSTAT3-inducible targets linked to cell survival andproliferation显示文摘 | Lassmann S Schuster I Walch A | 2007 | J Clin Pathol2007，60，2： | 1 |
| 7 | 信号转导和转录活化因子-1在上皮性卵巢癌中的表达及其与预后的关系显示文摘目的:探讨信号转导和转录活化因子(signal transducer and activator of transcription,STAT)-1在上皮性卵巢癌组织中的表达及其与预后的关系。方法:应用显微切割法从石蜡切片标本中提取mRNA,实时荧光定量PCR(real-time fluorogentic quantitative PCR,RFQ-PCR)和免疫组织化学方法检测105例原发性卵巢上皮癌和29例正常卵巢组织中STAT-1 mRNA及蛋白的表达,并分析其蛋白表达与预后的相关性。结果:上皮性卵巢癌组织中STAT-1 mRNA的表达高于正常卵巢组织[(0.96±1.05)vs(0.46±0.57),P=0.032],但mRNA表达水平与卵巢癌的手术分期、病理分级以及生存时间无关(P>0.05);上皮性卵巢癌组织中STAT-1和P-STAT-1蛋白的阳性表达率分别为72.4%和71.9%,显著高于正常卵巢组织(P<0.05),但蛋白表达水平与病理分级和手术分期无明显相关性(P>0.05)。在行辅助泰素化疗的病例组中STAT-1和P-STAT-1蛋白高表达患者的预后较好,总的生存时间长于低表达患者(P<0.05);STAT-1蛋白高表达的卵巢癌患者无瘤生存时间明显长于低表达患者(P<0.01)。结论:STAT-1在上皮性卵巢癌中存在异常表达,与紫杉醇类药物化疗后的预后密切相关。STAT-1可能是抑制肿瘤细胞生长的关键因子之一。 | 沈怡 LASSMANN S HASENBURG A GERALD G MARTIN W 王泽华 | 2009 | 肿瘤2009，29，8： | 1 |
| 8 | STAT3 mRNA and protein expression in colorectal cancer:effects on STAT3-inducible targets linked to cell survival and proliferation显示文摘 | Lassmann S Schuster I Walch A | 2007 | J Clin Pathol2007，60，2： | 1 |
| 9 | Epigenetics: development, dynamics and disease 显示文摘 | Vogel T Lassmann S | 2014 | Cell Tissue Res2014，356，3： | 1 |
| 10 | Gab2 signaling in chron- ic myeloid leukemia cells confers resistance to multiple Bcr-Abl in- hibitors显示文摘 | Lassmann S Werner M Waller CF | 2013 | Leukemia2013，27，1： | 1 |
| 11 | Role of S-100beta as potential autoantigen in an autoimmune disease of the inner ear显示文摘 | Lassmann S Gloddek J | 1999 | J Neuroimmunol1999，101，1： | 1 |
| 12 | Identification of gene signatures for invasive colorectal tumor cells显示文摘 | Wiese AH Auer J Lassmann S | 2007 | Cancer Detect Prev2007，31，4： | 1 |
| 13 | Identification of genesignatures for invasive colorectal tumor cells 显示文摘 | Wiese AH Auer J Lassmann S | 2007 | Cancer Detect Prey2007，31，4： | 1 |
| 14 | Alpha-folate receptor expression in epithelial ovarian carcinoma and non-neoplastic ovarian tissue 显示文摘 | Markert S Lassmann S Gabriel B | 2008 | Anticancer Res2008，28，6： | 1 |
| 15 | STAT3 mRNA and protein expression in colorectal cancer:effects on STAT3-inducible targets linked to cell survival and proliferation显示文摘 | Lassmann S Schuster I Walch A | 2007 | J Clin Pathol2007，60，2： | 1 |
| 16 | Identification of gene signatures for invasive colorectal tumor cells 显示文摘 | Wiese AH Auer J Lassmann S | 2007 | Cancer Detection and Prevention2007，31，4： | 1 |
| 17 | Identification of gene signatures for invasive colorectal tumor cells 显示文摘 | Wiese A H Auer J Lassmann S | 2007 | Cancer Detect Prev2007，31，4： | 1 |
| 18 | The activation status of neuroantigen-specific T cells in the target organ determines the clinical outcome of autoimmune encephalomyelitis显示文摘 | Kawakami N Lassmann S Li Z | 2004 | J Exp Med2004，199，： | 1 |
| 19 | Astroeyte- targeted ex pression of IL- 12 induces active cellular immune responses in the central nervous system and modulates experimental allergic encephalomyelitis显示文摘 | Pagenstecher A Lassmann S Carson MI | 2000 | J Immunol2000，164，44： | 1 |
| 20 | Identification of occult tumor cells in node negative lymph nodes of colorectal cancer patients by cytokeratin 20 gene and protein expression显示文摘 | Lassmann S Bauer M Rosenberg R | 2004 | Int J Colorectal Dis2004，19，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员